RET alterations occur in ~1.9% of pancreatic cancers (41) whereas wild-type RET, co-receptor GFRα1, and GDNF are overexpressed in 50-70% of pancreatic cancer cases (194, 195). This evidence concerns the gene GDNF and familial pancreatic carcinoma.